SXI Life Sciences
7.199,97
PKT
+55,10
PKT
+0,77
%
Werbung
Analysen zu SXI Life Sciences-Werten
Datum | Rating | Analyst | |
---|---|---|---|
18.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
18.10.19 | Novartis Neutral | UBS AG | |
17.10.19 | Roche overweight | Morgan Stanley | |
17.10.19 | Roche Neutral | Credit Suisse Group | |
17.10.19 | Roche buy | Deutsche Bank AG | |
17.10.19 | Roche overweight | Barclays Capital | |
17.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
17.10.19 | Roche overweight | JP Morgan Chase & Co. | |
17.10.19 | Roche buy | Goldman Sachs Group Inc. | |
16.10.19 | Roche overweight | Morgan Stanley | |
16.10.19 | Roche overweight | JP Morgan Chase & Co. | |
16.10.19 | Roche buy | Deutsche Bank AG | |
16.10.19 | Roche buy | Jefferies & Company Inc. | |
16.10.19 | Roche buy | Goldman Sachs Group Inc. | |
16.10.19 | Roche buy | UBS AG | |
15.10.19 | Roche buy | Jefferies & Company Inc. | |
11.10.19 | Roche overweight | JP Morgan Chase & Co. | |
08.10.19 | Roche buy | Goldman Sachs Group Inc. | |
07.10.19 | Novartis Neutral | UBS AG | |
07.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
07.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
04.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
02.10.19 | Roche overweight | JP Morgan Chase & Co. | |
30.09.19 | Roche buy | Deutsche Bank AG | |
30.09.19 | Roche overweight | JP Morgan Chase & Co. | |
17.09.19 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
17.09.19 | Roche buy | Goldman Sachs Group Inc. | |
17.09.19 | Roche buy | Deutsche Bank AG | |
17.09.19 | Roche buy | UBS AG | |
17.09.19 | Roche overweight | JP Morgan Chase & Co. | |
16.09.19 | Roche buy | UBS AG | |
16.09.19 | Roche buy | Deutsche Bank AG | |
16.09.19 | Novartis Hold | Deutsche Bank AG | |
13.09.19 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
13.09.19 | Novartis buy | Merrill Lynch & Co., Inc. | |
13.09.19 | Roche buy | Merrill Lynch & Co., Inc. | |
13.09.19 | Roche overweight | JP Morgan Chase & Co. | |
10.09.19 | Novartis Neutral | UBS AG | |
09.09.19 | Novartis Underweight | JP Morgan Chase & Co. | |
09.09.19 | Roche overweight | Barclays Capital |